IBDEI165 ; ; 06-AUG-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,20628,2)
 ;;=^61358
 ;;^UTILITY(U,$J,358.3,20629,0)
 ;;=V70.5^^109^1269^68
 ;;^UTILITY(U,$J,358.3,20629,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,20629,1,4,0)
 ;;=4^Health Exam-Group Survey
 ;;^UTILITY(U,$J,358.3,20629,1,5,0)
 ;;=5^V70.5
 ;;^UTILITY(U,$J,358.3,20629,2)
 ;;=^295595
 ;;^UTILITY(U,$J,358.3,20630,0)
 ;;=585.4^^109^1269^19
 ;;^UTILITY(U,$J,358.3,20630,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,20630,1,4,0)
 ;;=4^Chr Kidney Dis Stage IV
 ;;^UTILITY(U,$J,358.3,20630,1,5,0)
 ;;=5^585.4
 ;;^UTILITY(U,$J,358.3,20630,2)
 ;;=^332810
 ;;^UTILITY(U,$J,358.3,20631,0)
 ;;=202.80^^109^1269^3
 ;;^UTILITY(U,$J,358.3,20631,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,20631,1,4,0)
 ;;=4^Lymphoma Nec Unspec Site
 ;;^UTILITY(U,$J,358.3,20631,1,5,0)
 ;;=5^202.80
 ;;^UTILITY(U,$J,358.3,20631,2)
 ;;=^87701
 ;;^UTILITY(U,$J,358.3,20632,0)
 ;;=782.2^^109^1269^33
 ;;^UTILITY(U,$J,358.3,20632,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,20632,1,4,0)
 ;;=4^Local Suprficial Swellng
 ;;^UTILITY(U,$J,358.3,20632,1,5,0)
 ;;=5^782.2
 ;;^UTILITY(U,$J,358.3,20632,2)
 ;;=^71690
 ;;^UTILITY(U,$J,358.3,20633,0)
 ;;=401.9^^109^1269^13
 ;;^UTILITY(U,$J,358.3,20633,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,20633,1,4,0)
 ;;=4^Hypertension NOS
 ;;^UTILITY(U,$J,358.3,20633,1,5,0)
 ;;=5^401.9
 ;;^UTILITY(U,$J,358.3,20633,2)
 ;;=^186630
 ;;^UTILITY(U,$J,358.3,20634,0)
 ;;=355.9^^109^1269^12
 ;;^UTILITY(U,$J,358.3,20634,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,20634,1,4,0)
 ;;=4^Mononeuritis NOS
 ;;^UTILITY(U,$J,358.3,20634,1,5,0)
 ;;=5^355.9
 ;;^UTILITY(U,$J,358.3,20634,2)
 ;;=^78915
 ;;^UTILITY(U,$J,358.3,20635,0)
 ;;=171.9^^109^1269^2
 ;;^UTILITY(U,$J,358.3,20635,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,20635,1,4,0)
 ;;=4^Mal Neo Soft Tissue NOS
 ;;^UTILITY(U,$J,358.3,20635,1,5,0)
 ;;=5^171.9
 ;;^UTILITY(U,$J,358.3,20635,2)
 ;;=^267165
 ;;^UTILITY(U,$J,358.3,20636,0)
 ;;=117.9^^109^1269^1
 ;;^UTILITY(U,$J,358.3,20636,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,20636,1,4,0)
 ;;=4^Mycoses NOS
 ;;^UTILITY(U,$J,358.3,20636,1,5,0)
 ;;=5^117.9
 ;;^UTILITY(U,$J,358.3,20636,2)
 ;;=^87308
 ;;^UTILITY(U,$J,358.3,20637,0)
 ;;=415.19^^109^1269^14
 ;;^UTILITY(U,$J,358.3,20637,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,20637,1,4,0)
 ;;=4^Pulm Emb & Infarc NEC
 ;;^UTILITY(U,$J,358.3,20637,1,5,0)
 ;;=5^415.19
 ;;^UTILITY(U,$J,358.3,20637,2)
 ;;=^303285
 ;;^UTILITY(U,$J,358.3,20638,0)
 ;;=780.60^^109^1269^29
 ;;^UTILITY(U,$J,358.3,20638,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,20638,1,4,0)
 ;;=4^Fever NOS
 ;;^UTILITY(U,$J,358.3,20638,1,5,0)
 ;;=5^780.60
 ;;^UTILITY(U,$J,358.3,20638,2)
 ;;=^336764
 ;;^UTILITY(U,$J,358.3,20639,0)
 ;;=787.20^^109^1269^58
 ;;^UTILITY(U,$J,358.3,20639,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,20639,1,4,0)
 ;;=4^Dysphagia NOS
 ;;^UTILITY(U,$J,358.3,20639,1,5,0)
 ;;=5^787.20
 ;;^UTILITY(U,$J,358.3,20639,2)
 ;;=^335307
 ;;^UTILITY(U,$J,358.3,20640,0)
 ;;=786.30^^109^1269^45
 ;;^UTILITY(U,$J,358.3,20640,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,20640,1,4,0)
 ;;=4^Hemoptysis NOS
 ;;^UTILITY(U,$J,358.3,20640,1,5,0)
 ;;=5^786.30
 ;;^UTILITY(U,$J,358.3,20640,2)
 ;;=^339669
 ;;^UTILITY(U,$J,358.3,20641,0)
 ;;=787.60^^109^1269^62
 ;;^UTILITY(U,$J,358.3,20641,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,20641,1,4,0)
 ;;=4^Incontinence of Feces
 ;;^UTILITY(U,$J,358.3,20641,1,5,0)
 ;;=5^787.60
 ;;^UTILITY(U,$J,358.3,20641,2)
 ;;=^339670
 ;;^UTILITY(U,$J,358.3,20642,0)
 ;;=294.20^^109^1269^10
 ;;^UTILITY(U,$J,358.3,20642,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,20642,1,4,0)
 ;;=4^Dementia NOS
 ;;
 ;;$END ROU IBDEI165
